Tesamorelin

# Tesamorelin (TH9507, brand names Egrifta / Egrifta SV)

>

> ⚠️ The research-grade version is intended for laboratory research only; the finished injectable formulation is an FDA-approved prescription drug, and its use in humans for non-medical purposes is prohibited.

## Basic Information

– CAS: 218949-48-5 (free base); Acetate CAS: 901758-09-6

– Synonyms: TH9507, GHRH (1-44) analog

– Molecular formula: \(\boldsymbol{C_{221}H_{366}N_{72}O_{67}S}\) (free base)

– Molecular Weight: 5135.78 Da

– Amino Acids: 44-peptide, N-terminally modified with trans-3-hexenoyl, C-terminally amidated

– Sequence: trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln -Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂

– Appearance: White lyophilized powder

– Solubility: Easily soluble in BAC bacteriostatic water / AA sterile water

Mechanism of Action

Tesamorelin is a stable analog of GHRH (growth hormone-releasing hormone) with an N-terminal modification that resists degradation by the DPP4 enzyme:

1. Binds to the pituitary GHRH receptor, stimulating pulsatile release of endogenous GH; it is not direct exogenous GH

2. GH promotes IGF-1 secretion by the liver

3. Targets visceral adipose tissue (VAT) breakdown, prioritizing the reduction of deep abdominal fat; subcutaneous fat is minimally affected, resulting in minimal weight change

4. Preserves the body’s natural GH negative feedback regulation; unlike DAC-modified CJC-1295, it does not sustain elevated GH levels

Clinically Approved Indication: Patients with HIV-associated dyslipidemia to reduce excessive intra-abdominal visceral fat (Egrifta SV)

## Pharmacokinetics (Research Reference)

– Half-life: Approximately 26–38 minutes after subcutaneous injection

– Onset of action: A single dose produces a single GH pulse; no prolonged accumulation

– Listed as a WADA Prohibited Substance (Category S2); prohibited in competitive sports

Reconstitution & Storage (Laboratory Procedures)

1. Solvent: BAC bacteriostatically treated water / AA sterile water

2. Example: 2 mg lyophilized vial + 1 mL BAC water → concentration 2 mg/mL

3. Lyophilized powder: Store at -20°C, protected from light and in a sealed container; stable

4. After reconstitution: Refrigerate at 2–8°C; use within 2–4 weeks; avoid repeated freeze-thaw cycles

## Compliance Notes

1. Research-grade Tesamorelin is intended solely for in vitro / animal experiments; human injection is strictly prohibited

2. The finished product Egrifta is an FDA-approved prescription drug; it may only be used under a doctor’s prescription for the indicated conditions